TRPV3 and Olmsted syndrome 1: Finally, targeting Trpv3 via PVLP delivery of SaCas9 or shRNA was remarkably efficient in primary keratinocytes and resulted in rescue of Olmsted syndrome phenotypes in ex vivo mouse skin equivalents.